ARTICLE

Synthesis of spirocycles *via* ring closing metathesis of heterocycles carrying gem-diallyl substituents obtained via ring opening of (halomethyl)cyclopropanes with allyltributyltin

www.rsc.org/obc

Mukund K. Gurjar,^{*} Somu V. Ravindranadh,^a Kuppusamy Sankar,^a Sukhen Karmakar,^a Joseph Cherian^{*a*} and Mukund S. Chorghade^{*b*}

^a National Chemical Laboratory, Pune, 411 008, India

^b Chorghade Enterprises, 14 Carlson Circle, Natick, MA 01760, USA

Received 9th January 2003, Accepted 10th February 2003 First published as an Advance Article on the web 20th March 2003

In the presence of allyl tri-n-butyltin-AIBN, cyclopropylmethyl bromides/xanthates undergo ring-opening reaction with concomitant formation of geminal diallyl derivatives in good yields. The ring closing metathesis reactions on geminal diallyl derivatives with Grubbs' catalyst provided spirocyclopentenyl products. Combination of these two methodologies has been applied to the synthesis of mono-, bis-cyclopentyl-carbohydrates as well as spirocyclopentylproline derivatives.

Introduction

Interest in developing new protocols that can give rise to spiro derivatives has risen considerably, primarily due to the inherent rigidity displayed by the spiro functionality.¹ Molecules containing a spiro group find innumerable applications particularly in peptides,² nucleosides³ and carbohydrates.⁴ The synthesis of spiro derivatives was difficult until the advent of novel catalysts by Schrock⁵ and Grubbs⁶ used in ring closing metathesis (RCM). The RCM based approaches⁷ have made the introduction of a spiro group in the structural framework of an organic molecule an easy proposition.8 For instance, gem-diallyl containing substrates undergo RCM to produce spirocyclopentene derivatives.9

The synthesis of gem-diallyl derivatives can be realized by double alkylation of an active methylene group.¹⁰ We realized that the introduction of a gem-diallyl functionality on a carbon atom not activated by any electron-withdrawing group, is a difficult proposition. The problem becomes insurmountable when a carbohydrate precursor is involved because base catalysed reactions lead to tandem elimination of water molecules, resulting in the formation of a mixture of compounds.

Some years ago, we observed interesting reactions¹¹ with carbohydrate cyclopropyl precursors. For example, the radical mediated cyclopropyl scission of the spirocyclopropyl bromide 1 with n-Bu₃SnH gave the C-allyl derivative 2 in a stereocontrolled fashion. On the other hand, hydrogenation of the cyclopropyl-aldehyde derivative 3 over Pd/C provided 4 with a quaternary chiral center (Scheme 1).

We were particularly impressed by the radical ring opening reaction as described above because we envisaged that in situ quenching of the homoallyl radical formed (Fig. 1) with allyltri-n-butyltin¹² should lead to the formation of a gem-diallyl derivative. This study forms the main objective of this manuscript.13



Results and discussion

The requisite precursor 1, earlier reported¹¹ from our laboratory, was treated with allyltri-n-butyltin in refluxing benzene



and catalytic AIBN to give the gem-diallyl derivative 5 in 76% yield (Scheme 2). The structure of 5 was proven, beyond any doubt, by ¹H, ¹³C, mass spectroscopy and elemental analysis.



Scheme 2 Reagents and conditions: (a) allyltri-n-butyltin, C₆H₆, AIBN, 80 °C. 76%

In order to establish the versatility of this reaction, a number of spirocyclopropylmethyl bromides were prepared (Table 1), according to the general strategy depicted in Scheme 3. The carbonyl derivative was subjected to the Wittig reaction with Ph₃P=CHCO₂Et in refluxing benzene. For entries 1-3, the resulting unsaturated ester was cyclopropanated 14 with Me₃-S(O)I-NaH in DMSO and then reduced with DIBAL-H in CH₂Cl₂ at -78 °C to afford the cyclopropylmethanol derivatives. For entry 4, the unsaturated ester was first reduced with DIBAL-H in CH₂Cl₂ at -78 °C to provide an allylic alcohol which was subsequently cyclopropanated (entry 5 as well) using the modified Simmons-Smith method¹⁵ by using Et₂Zn-CH₂I₂ in CH₂Cl₂ at -20 °C. Conversion of the cyclopropyl-



Scheme 3 Reagents and conditions: (a) PPh₃=CHCO₂Et, C₆H₆, 80 °C; (b) Me₃SOI, DMSO, NaH; (c) DIBAL-H, CH₂Cl₂, -78 °C; (d) CBr₄, PPh₃, CH₂Cl₂, py or NaH, CS₂, MeI, THF; (e) Et₂Zn, CH₂L₂, -20 °C.

 Table 1
 Synthesis of gem-diallyl compounds from (halomethyl)cyclopropanes



methanol to the corresponding cyclopropylmethyl bromide was accomplished with CBr_4 -Ph₃P-pyridine in CH_2Cl_2 at room temperature.

The preparation of the xanthate derivative (entry 6) from the cyclopropylmethanol was accomplished using a well-defined protocol using CS_2 -NaH-MeI in THF. The bromoxanthate derivatives (entries 1–6) were treated with allyltri-*n*-butyltin-AIBN in refluxing benzene to provide the *gem*-diallyl product in good yields. The diallyl derivatives were fully characterized by spectroscopic methods.

Application of this concept to install two different allylic functionalities on the same carbon was also explored when methallyltri-*n*-butyltin was treated with **1** to give rise to 3-deoxy-3-*C*-allyl-3-*C*-methallyl derivative **20** (Scheme 4). The absolute stereochemistry of **20** was established by NOE studies as indicated in Fig. 2.

Having in hand the gem-diallyl derivatives, our next target



Scheme 4 Reagents and conditions; (a) methally ltributyltin, C_6H_6 , AIBN, 80 °C, 12 h, 52%.

was to perform ring closing metathesis reactions⁷ in order to convert them to novel spirocyclopentyl derivatives. For instance, compound **5** was treated with Grubbs' catalyst in CH_2Cl_2 at room temperature to provide the spirocyclopentenyl derivative **21** whose structure was supported by spectroscopic data. Interestingly the RCM reaction of **20** gave **22** in 75% yield (Scheme 5).



Scheme 5 Reagents and conditions; (a) Grubbs' catalyst, CH_2Cl_2 , rt, 80%; (b) Grubbs' catalyst, CH_2Cl_2 , rt, 75%.

Our next plan was to adopt an iterative approach of the above two strategies and prepare some novel bis-spirocyclopentyl derivatives of carbohydrates. For this endeavor, compound **21**was subjected to hydroboration–oxidation reaction, which led to the formation of a complex mixture of diastereomers (Scheme 6). The mixture as such was oxidized under Swern oxidation conditions to give two products (**23** and **24**), separated by silica gel chromatography. The correct assignment of the structures of **23⁴** and **24** was performed by NOE experiments (Fig. 3).



Scheme 6 Reagents and conditions; (a) BH₃·SMe₂, NaOAc, 30% H₂O₂, THF, 0 °C, 1 h; (b) (COCl)₂, Me₂SO, CH₂Cl₂, Et₃N, -78 °C, 2 h, 56%.



Compound 23 was subjected to the following sequence of reactions: Wittig olefination with $(EtO)_2P(O)CH_2CO_2Et$, reduction of ester group with DIBAL-H to obtain 25, Simmons–Smith cyclopropanation and the corresponding xanthate preparation with NaH–CS₂–MeI in THF (Scheme 7).

The radical induced diallylation of xanthate gave **26** whose RCM reaction and catalytic hydrogenation produced the bis-spiro-derivative **28**.



Scheme 7 Reagents and conditions; (a) (EtO)₂P(O)CH₂COOEt, NaH, THF, 0 °C → rt, 80%; (b) DIBAL-H, CH₂Cl₂, -78 °C, 0.5 h, 88%; (c) Et₂Zn, CH₂I₂, CH₂Cl₂, -20 °C, 14 h, 60%; (d) NaH, CS₂, MeI, THF, 0.5 h, 90%; (e) allyltributyltin, C₆H₆, AIBN, 80 °C, 34%; (f) Grubbs² catalyst, CH₂Cl₂, rt, 4 h, 88%; (g) 10% Pd/C–H₂, MeOH, 82%.

In a similar manner, the other isomer (24) was also converted to the diallyl derivative 29 and the bis-spiro-derivative 30 (Scheme 8).



Spiroproline derivatives are of interest in biological studies with potential applications as an inhibitor and mechanistic probe of prolyl-4-hydroxylase.²⁰ In pursuit of the development of potent inhibitors of angiotensin converting enzyme (ACE), lipophilic and sterically hindered spiroproline derivatives have been substituted in the structural framework of peptides. In addition, spiroprolines could offer interesting scaffold precursors, particularly in the synthesis of combinatorial libraries of peptides. The earlier synthetic efforts aimed at spiroproline analogues involved building the proline nucleus on the structural backbone of the alicyclic system followed by resolution. We decided to try to expand the potential of our synthesis of spirocyclic compounds to proline derivatives, with the hitherto unknown 2-azaspiro[4.4]nonanecarboxylic acid derivative **39** as the target.

The known *trans-N-(p-*toluenesulfonyl)-4-hydroxy-L-prolinol (**31**)²¹ was converted into 4,4'-cyclopentyl-L-proline derivative by essentially following the route already discussed and shown in Scheme 9. The purity of the final product was determined by chiral HPLC (95%). The structure of **39** was supported by its ¹H-NMR, ¹³C-NMR, and mass spectral data.

Conclusions

We have derived a simple protocol to introduce a *gem*-diallyl group. The RCM reaction provided a strategy for the preparation of spirocyclopentyl derivatives of sugars and L-proline.

Experimental

NMR spectra were recorded on Bruker AC 200, MSL 300 or DRX 500 MHz instruments in $CDCl_3$ or acetone-D₆ using TMS as internal standard. IR spectra were recorded on a Perkin–Elmer 16 PC–FT IR spectrometer. Electron impact mass spectra (EIMS) were recorded on a Finnigan MAT–1020.



Microanalysis was carried out on a Carlo–Elba elemental analyzer. Melting points were measured on a Buchi B-540 apparatus and are uncorrected. Optical rotations were recorded on a JASCO DIP-1020 digital polarimeter. Solvents were distilled over drying agents under argon or nitrogen. All reactions were monitored by thin-layer chromatography carried out on 0.25 m E. Merck silica gel plates (60F–254) using UV light as visualizing agent and anisaldehyde in ethanol as developing agent. Silica gel (60–120) was purchased from Acme Chemical Company.

General procedure for cyclopropanation with Me₃S(O)I

To the mixture of Me₃S(O)I (2.0 eq.) and NaH (2.0 eq.) in DMSO at 0 °C was added a solution of α , β -unsaturated ester in dry DMSO under argon. After 2 h, the reaction was quenched with water and extracted with ether, washed with brine, dried and concentrated. The residue was purified by column chromatography on silica gel.

General procedure for cyclopropanation with Et₂Zn

To a solution of the allylic alcohol in dry CH_2Cl_2 under argon at -20 °C was added a 1 M solution of Et_2Zn (3.0 eq.) and CH_2I_2 (6.0 eq.). After 12 h, the reaction was quenched with ice and partitioned between CH_2Cl_2 and water. The organic layer was dried, concentrated and the residue passed through a short column of silica gel.

General procedure for the preparation of cyclopropylmethyl bromides

To the stirred solution of the cyclopropylmethanol in dry CH_2Cl_2 at rt was added pyridine, triphenylphosphine (2.2 eq.) and CBr_4 (1.1 eq.) successively. After 30 min solvent was removed *in vacuo* and the residue was passed through a short bed of silica gel.

General procedure for the preparation of xanthates

 CS_2 (4.0 eq.) was added to a previously stirred solution of the cyclopropylmethanol and NaH (2.0 eq.) in dry THF at 0 °C

under N_2 followed by CH_3I (5.0 eq.). After 30 min the reaction was quenched with saturated aq. NH_4Cl , extracted with CH_2Cl_2 and washed with water, brine and dried. The crude product was purified by column chromatography on silica gel.

General procedure for diallylation

A solution of the cyclopropylmethyl bromide/xanthate, allyltri*n*-butyltin (2.0 eq.) and AIBN (cat.) in benzene was degassed and refluxed under argon for 12 h. The reaction mixture was concentrated, diluted with ether and stirred with an aq. solution of KF for 3 h and then filtered. The filtrate was washed with water, dried (Na_2SO_4), concentrated and the residue purified by column chromatography on silica gel.

General procedure for RCM

A solution of the *gem*-diallyl compound and Grubbs' catalyst (5 mol%) in CH_2Cl_2 was stirred at rt for 3 h. Solvent was removed and the crude product purified by column chromatography on silica gel.

3-Deoxy-1,2:5,6-di-*O*-isopropylidene-3,3-*C*-diallyl-α-D-*ribo*-hexofuranose (5)

Following the general procedure for diallylation, compound 1¹¹ (0.19 g, 0.52 mmol), allyltri-*n*-butyltin (0.35 mL, 1.0 mmol) and AIBN (10 mg) in benzene (6 mL) gave compound **5** (0.13 g, 76%); $[a]_{\rm D}$ + 36 (*c* 2.1 in CHCl₃); $\delta_{\rm H}$ (300 MHz; CDCl₃) 1.27, 1.33, 1.45, 1.50 (4 s, 12 H), 2.15–2.45 (m, 4 H), 3.72 (m, 1H), 3.78 (m, 1 H), 4.09 (m, 2 H), 4.24 (d, 1 H, *J* 3.4 Hz), 5.03 (m, 4 H), 5.57 (d, 1 H, *J* 3.4 Hz), 5.90 (m, 2 H); $\delta_{\rm C}$ (50 MHz; CDCl₃) 25.5, 26.4, 26.8, 27.1, 36.1, 37.0, 50.6, 69.0, 73.5, 85.2, 86.0, 104.4, 109.5, 111.3, 117.6, 134.8, 135.5 (Found: C, 66.46; H, 8.92. C₁₈H₂₈O₅ requires C, 66.64; H, 8.70%).

Methyl 3-*O*-benzyl-5,6-*O*-cyclohexylidene-2-deoxy-2,2-*C*-[(hydroxymethyl)ethylene]-β-D-*arabino*-hexofuranoside (8)

A mixture of compound 7^{16} (3.6 g, 10.0 mmol) and PPh₃= CHCO₂Et (5.2 g, 15.0 mmol) was refluxed in benzene (20 mL) for 4 h and concentrated. The residue was purified by passing through a bed of silica gel (light petroleum-EtOAc 20:1) to afford the unsaturated ester (3.2 g) which was treated with Me₃S(O)I (3.2 g, 14.8 mmol) and NaH (0.6 g, 14.8 mmol) in dry DMSO (10 ml), as per general procedure, to give the cyclopropyl derivative (1.3 g). It was dissolved in dry CH₂Cl₂ (10 mL) and cooled to -78 °C. DIBAL-H solution (2.0 molar solution, 3.7 mL, 7.4 mmol) was introduced, stirred for 1 h, and treated with saturated solution of sodium potassium tartrate. The organic layer was separated, dried (Na_2SO_4) and evaporated. The resulting residue was purified on silica gel with ethyl acetate-light petroleum (2:3) to give methyl 3-O-benzyl-5,6-cyclohexylidene-2-deoxy-2,2-[(hydroxymethyl)ethylene]-β-D-*arabino*-hexofuranoside **8** (0.93 g, 23%); $[a]_{D}$ + 82 (c 0.5 in CHCl₃); $\delta_{\rm H}$ (200 MHz; CDCl₃) 0.75 (dd, 1 H, J 5.8, 8.8 Hz), 0.9 (t, 1 H, J 5.8 Hz), 1.39-1.75 (m, 11 H), 2.31 (br s, 1 H), 3.26 (dd, 1 H, J 8.8, 11.7 Hz), 3.34 (s, 3 H), 3.59 (d, 1 H, J 3.8 Hz), 3.71 (dd, 1 H, J 5.9, 11.7 Hz), 3.97–4.21 (m, 4 H), 4.38 (m, 1 H), 4.64 (d, 1 H, J 11.6 Hz), 4.79 (d, 1 H, J 11.6 Hz), 4.86 (s, 1 H), 7.32 (m, 5 H) (Found: C, 68.40; H, 7.68. C₂₃H₃₂O₆ requires C, 68.29; H, 7.97%).

Methyl 3-*O*-benzyl-5,6-*O*-cyclohexylidene-2-deoxy-2,2-*C*-diallyl-β-D-*arabino*-hexofuranoside (9)

Following the general procedure, compound **8** (1.6 g, 4.0 mmol), PPh₃ (2.3 g, 8.8 mmol), CBr₄ (1.5 g, 4.4 mmol) and pyridine (0.3 mL) gave the corresponding cyclopropyl-methylbromide (purified by passing through a short bed of silica gel, eluting with ethyl acetate-light petroleum-1:9, 1.3 g). Following the general procedure for diallylation, the cyclo-

propylmethyl bromide (1.3 g, 2.8 mmol), allyltri-*n*-butyltin (1.8 ml, 5.6 mmol) and AIBN (10 mg) gave **9** (0.75 g, 44%); $[a]_{\rm D}$ + 66 (*c* 0.41 in CHCl₃); $\delta_{\rm H}$ (500 MHz; CDCl₃) 1.58 (m, 10 H), 2.05–2.40 (m, 4 H), 3.31 (s, 3 H), 3.90 (d, 1 H, *J* 4.4 Hz), 3.95 (dd, 1 H, *J* 5.9, 8.3 Hz), 4.08 (m, 2 H), 4.31 (m, 1 H), 4.49 (d, 1 H, *J* 11.0 Hz), 4.71 (s, 1 H), 4.74 (d, 1 H, *J* 11.0 Hz), 5.06 (m, 4 H), 5.77 (m, 2 H), 7.31 (m, 5 H); $\delta_{\rm C}$ (125 MHz; CDCl₃) 23.9, 24.1, 25.2, 35.0, 35.3, 36.5, 52.6, 55.9, 67.2, 73.2, 74.2, 80.4, 84.4, 109.2, 109.6, 117.5, 117.7, 127.6–128.3, 135.0, 138.5 (Found: C, 72.73; H, 8.44. C₂₆H₃₆O₅ requires C, 72.87; H, 8.47%).

(*E*)-5-*O*-(*tert*-Butyldiphenylsilyl)-3-deoxy-1,2-*O*-isopropylidene-3,3-*C*-[(hydroxymethyl)ethylene]-α-D-*threo*-pentofuranose (11)

Cyclopropanation of **10**¹⁷ (3.5 g, 7.0 mmol) was carried out as per the general procedure using NaH (0.56 g, 14.1 mmol) and Me₃S(O)I (3.1 g, 14.1 mmol) in DMSO (10 mL). The cyclopropanated product (2.1 g, 4.2 mmol) was reduced with DIBAL-H (2 M solution, 4.7 mL, 9.4 mmol) at -78 °C as reported before to obtain **11** (1.6 g, 48%); [a]_D + 11.1 (c 2.1in CHCl₃); $\delta_{\rm H}$ (300 MHz; CDCl₃) 0.5 (t, 1H, J 5.1 Hz), 0.97 (s, 9H), 1.08 (m, 2H), 1.26, 1.52 (2s, 6H), 3.16 (t, 1H, J 11.4 Hz), 3.29 (dd, 1H, J 6.2, 10.6 Hz), 3.56 (dd, 1H, J 4.7, 10.6 Hz), 4.36 (m, 2H), 5.79 (d, 1H, J 3.6 Hz), 7.40 (m, 5H), 7.65 (m, 5H); $\delta_{\rm C}$ (75 MHz; CDCl₃) 12.5, 19.1, 20.7, 26.6, 26.8, 27.1, 33.8, 63.5, 65.1, 78.5, 86.4, 104.6, 111.7, 127.7, 129.8, 133.0, 135.6; MS (EI) m/z 255 (M⁺ – O'BuSiPh₂) (Found: C, 68.96; H, 7.87. C₂₇H₃₆O₅Si requires C, 69.20; H, 7.74%).

5-*O*-(*tert*-Butyldiphenylsilyl)-3-deoxy-3,3-*C*-diallyl-1,2-*O*-iso-propylidene-α-D-*threo*-pentofuranose (12)

As per the general procedure, **11** (0.6 g, 1.3 mmol) was converted to the corresponding cyclopropylmethyl bromide using Ph₃P (0.7 g, 2.8 mmol), CBr₄ (0.5 g, 1.4 mmol) and pyridine (0.5 mL) in CH₂Cl₂ (25 mL). The cyclopropylmethyl bromide thus obtained (0.61 g, 1.2 mmol) was treated with allyltri-*n*-butyltin (0.74 mL, 2.4 mmol) and AIBN (5 mg) by following the general procedure for diallylation, to afford **12** (0.45 g, 81%); [*a*]_D + 22 (*c* 1.0 in CHCl₃); $\delta_{\rm H}$ (200 MHz; CDCl₃) 1.08 (s, 9 H), 1.29 (s, 3 H), 1.54 (s, 3 H), 1.87–2.54 (m, 4 H), 3.82 (m, 2 H), 4.03 (t, 1 H, *J* 6.5 Hz), 4.25 (d, 1 H, *J* 3.4 Hz), 5.0 (m, 4 H), 5.70 (d, 1 H, *J* 3.4 Hz), 5.80 (m, 2 H), 7.35–7.77 (m, 10 H); $\delta_{\rm c}$ (50 MHz; CDCl₃) 19.3, 26.5, 27.0, 35.6, 36.5, 50.0, 62.9, 84.7, 85.6, 104.2, 111.0, 117.7, 127.8, 129.8, 133.3–135.7; MS (EI) *m*/*z* 257 (M⁺ – *t*-BuSiPh₂) (Found: C, 73.19; H, 8.28. C₃₀H₄₀-O₄Si requires C, 73.13; H, 8.18%).

(4-Methoxyspiro[2.5]octan-1-yl)methanol (14)

To a solution of 13¹⁸ (0.6 g, 3.0 mmol) in dry CH₂Cl₂ (25 mL) under argon atmosphere at -78 °C was added a 2.1 M solution of DIBAL-H (3.6 mL, 7.6 mmol). After stirring for 1 h at -78 °C, the reaction mixture was worked up in the usual fashion to give a residue, which was purified by silica gel chromatography (EtOAc-light petroleum 1 : 9) to give 2-(2methoxycyclohexylidene)ethanol (0.4 g). Following the general procedure for cyclopropanation, 2-(2-methoxycyclohexylidene)ethanol (0.4 g, 2.6 mmol), a 1 M solution of Et₂Zn (7.8 mL, 7.8 mmol) and CH₂I₂ (1.2 mL, 15.6 mmol) in dry CH₂Cl₂ (25 mL) gave 14 (0.29 g, 56%); $\delta_{\rm H}$ (200 MHz; CDCl₃) 0.14 (t, 1 H, J 5.1 Hz), 0.47 (dd, 1 H, J 5.1, 8.8 Hz), 1.25-1.95 (m, 9 H), 2.53 (s, 1 H), 2.96 (br s, 1 H), 3.34 (s, 3 H), 3.53 (dd, 1 H, J 8.8, 11.0 Hz), 3.68 (m, 1 H); δ_C (50 MHz; CDCl₃) 13.7, 21.0, 24.9, 25.4, 25.9, 26.0, 28.7, 56.1, 62.2, 83.9; MS (EI) *m*/*z* 170 (M⁺).

1,1-Diallyl-2-methoxycyclohexane (15)

Following the general procedure of bromination, compound 14 (0.25 g, 1.5 mmol), Ph_3P (0.85 g, 3.2 mmol), CBr_4 (0.54 g,

1.6 mmol) and pyridine (0.5 mL) gave the corresponding cyclopropylmethyl bromide (0.27 g). As per general procedure, the cyclopropylmethyl bromide (0.27 g, 1.2 mmol), allyltri-*n*-butyltin (0.7 mL, 2.4 mmol) and AIBN (20 mg) gave **15** (0.17 g, 60%); $\delta_{\rm H}$ (200 MHz; CDCl₃) 1.10–1.80 (m, 8 H), 1.92–2.30 (m, 4 H), 2.94 (dd, 1 H, *J* 3.4, 7.8 Hz), 3.27 (s, 3 H), 4.94 (m, 4 H), 5.77 (m, 2 H); $\delta_{\rm C}$ (50 MHz; CDCl₃) 21.0, 22.9, 24.1, 31.4, 36.8, 39.8, 40.9, 56.3, 82.3, 117.0, 117.2, 135.1; MS (EI) *m*/*z* 194 (M⁺) (Found: C, 80.62; H, 11.53. C₁₃H₂₂O requires C, 80.35; H, 11.41%).

{2-(Benzyloxymethyl)cyclopropyl}methanol (17)

Cyclopropanation of **16**¹⁹ (1.4 g, 7.8 mmol) was achieved by following the general procedure using Et₂Zn (1 M solution, 23.5 mL, 23.5 mmol) and CH₂I₂ (3.8 mL, 47.2 mmol) in CH₂Cl₂ (50 mL) at -20 °C to yield **17** (0.79 g, 52%); $\delta_{\rm H}$ (300 MHz; CDCl₃) 0.20 (dd, 1 H, *J* 2.9, 7.0 Hz), 0.8 (m, 1 H), 1.33 (m, 2 H), 2.96 (s, 1 H), 3.14 (m, 2 H), 3.90 (m, 2 H), 4.55 (m, 2 H), 7.33 (m, 5 H); $\delta_{\rm c}$ (50 MHz; CDCl₃) 8.6, 14.8, 18.5, 62.9, 70.7, 73.1, 127.9, 128.5, 137.5; MS (EI) *m*/*z* 161 (M⁺ – CH₂OH), 101 (M⁺ – OBn).

2-Allylpent-4-enyl benzyl ether (18)

Compound **17** (0.4 g, 2.1 mmol) was treated with PPh₃ (1.2 g, 4.6 mmol), CBr₄ (0.76 g, 2.3 mmol) and pyridine (1.5 mL) in CH₂Cl₂ (10 mL) as per the general procedure for bromination. The resulting cyclopropylmethyl bromide derivative (0.4 g, 1.6 mmol) was reacted with allyltri-*n*-butyltin (1.0 mL, 3.2 mmol) according to the general procedure for diallylation, to give **18** (0.24 g, 53%); $\delta_{\rm H}$ (200 MHz; CDCl₃) 1.76 (m, 1 H), 2.10 (m, 4 H), 3.33 (dd, 2 H, *J* 5.9, 11.2 Hz), 4.46 (d, 2 H, *J* 11.7 Hz), 5.00 (m, 4 H), 5.73 (m, 2 H), 7.26 (m, 5 H); $\delta_{\rm C}$ (50 MHz; CDCl₃) 35.4, 38.3, 72.4, 73.1, 116.3, 127.5, 128.3, 136.7; MS (EI) *m*/*z* 216 (M⁺) (Found: C, 83.35; H, 9.47. C₁₅H₂₀O requires C, 83.29; H, 9.32%).

3-Deoxy-1,2:5,6-di-*O*-isopropylidene-3,3-*C*-[*S*-methyldithiocarbonylmethylethylene]-α-D-*ribo*-hexofuranose (19)

Following the general procedure for the preparation of xanthate, **6** (0.22 g, 0.73 mmol), NaH (0.059 g, 1.5 mmol) and CH₃I (0.3 ml, 4.9 mmol) gave compound **19** (0.26 g, 92%); $[a]_{\rm D}$ + 97 (*c* 1.0 in CHCl₃); $\delta_{\rm H}$ (200 MHz; CDCl₃) 0.71 (t, 1 H, *J* 5.6 Hz), 1.27 (s, 6 H), 1.33 (m, 1 H), 1.36, 1.52 (2 s, 6 H), 1.81 (m, 1 H), 2.57 (s, 3 H), 3.72 (ddd, 1 H, *J* 9.3, 5.2, 6.4 Hz), 3.92 (dd, 1 H, *J* 9.3 Hz), 4.32 (d, 1 H, *J* 3.9 Hz), 4.48 (dd, 1 H, *J* 9.3, 11.8 Hz), 4.97 (dd, 1 H, *J* 5.4, 11.8 Hz), 5.97 (d, 1 H, *J* 3.9 Hz); $\delta_{\rm C}$ (50 MHz; CDCl₃) 13.7, 16.4, 18.8, 25.3, 26.7 (2C), 27.0, 34.5, 68.1, 75.0, 75.5, 79.0, 86.3, 104.7, 109.5, 111.9, 215.7 (Found: C, 52.23; H, 6.87; S, 16.63. C₁₇H₂₆O₆S₂ requires C, 52.29; H, 6.71; S, 16.42%).

3-Deoxy-1,2:5,6-di-*O*-isopropylidene-3-*C*-allyl-3-*C*-methallyl-α-D-*ribo*-hexofuranose (20)

By following the general procedure for diallylation, compound 1^{11} (0.2 g, 0.55 mmol), methallyltri-*n*-butyltin (0.5 g, 1.4 mmol) and AIBN (5 mg) gave **20** (97 mg, 52%); $[a]_D$ + 57 (*c* 0.7 in CHCl₃); δ_H (200 MHz; CDCl₃) 1.32 (s, 3 H), 1.36 (s, 3 H), 1.43 (s, 3 H), 1.54 (s, 3 H), 1.86 (s, 3 H), 2.10 (d, 1 H, *J* 13.3 Hz), 2.35 (d, 1 H, *J* 13.3 Hz), 2.47 (d, 2 H, *J* 7.8 Hz), 3.89 (m, 2 H), 4.09–4.33 (m, 2 H), 4.49 (d, 1 H, *J* 3.9 Hz), 4.76 (s, 1 H), 4.91 (s, 1 H), 5.05 (s, 1 H), 5.11 (m, 1 H), 5.61 (d, 1 H, *J* 3.5 Hz), 6.02 (m, 1 H); MS (EI) *m/z* 338 (M⁺) (Found: C, 67.51; H, 8.90. C₁₉H₃₀O₅ requires C, 67.43; H, 8.93%).

3-Deoxy-1,2:5,6-di-*O*-isopropylidene-α-D-*ribo*-hexofuranose-3-spiro-3-cyclopentene (21)

Following the general procedure for RCM, compound 5 (0.10 g, 0.3 mmol) and Grubbs' catalyst (5 mg) in CH_2Cl_2 (8 mL) gave

View Article Online

21 (73 mg, 80%), $[a]_{\rm D}$ + 43 (*c* 0.9 in CHCl₃); $\delta_{\rm H}$ (200 MHz; CDCl₃) 1.31 (s, 6 H), 1.40 (s, 3 H), 1.50 (s, 3 H), 1.79 (m, 1 H), 2.57 (m, 3 H), 3.96 (m, 2 H), 4.10 (m, 2 H), 4.24 (d, 1 H, *J* 3.7 Hz), 5.69 (m, 3 H); $\delta_{\rm C}$ (50 MHz; CDCl₃) 25.4, 26.4, 26.7, 27.0, 34.9, 36.3, 55.1, 68.3, 74.5, 81.6, 87.2, 103.9, 109.2, 111.7, 127.3, 130.2; MS (EI) *m*/*z* 281 (M - Me) ⁺ (Found: C, 64.75; H, 8.23. C₁₆H₂₄O₅ requires C, 64.84; H, 8.16%).

3-Deoxy-1,2:5,6-di-*O*-isopropylidene-α-D-*ribo*-hexofuranose-3spiro-3-(3-methylcyclopentene) (22)

Following the general procedure for RCM, compound **20** (75 mg, 0.22 mmol) and Grubbs' catalyst (5 mg) in CH₂Cl₂ (5 mL) gave **22** (52 mg, 75%) $[a]_{\rm D}$ + 46 (*c* 0.45 in CHCl₃); $\delta_{\rm H}$ (200 MHz; CDCl₃) 1.25 (s, 3 H), 1.32 (s, 3 H), 1.41 (s, 3 H), 1.53 (s, 3 H), 1.73 (s, 3 H), 2.57 (m, 4 H), 3.97 (m, 2 H), 4.12 (m, 2 H), 4.26 (d, 1 H, *J* 3.4 Hz), 5.31 (br s, 1 H), 5.70 (d, 1 H, *J* 3.4 Hz); $\delta_{\rm C}$ (50 MHz; CDCl₃) 25.4, 26.4, 26.7, 27.0, 29.7, 34.9, 40.7, 55.8, 68.2, 74.7, 81.8, 87.4, 104.1, 109.3, 111.8, 123.6, 136.9; MS (EI) *m*/*z* 295 (M - Me)⁺ (Found: C, 65.82; H, 8.63. C₁₇H₂₆O₅ requires C, 65.78; H, 8.44%).

(3*R*)-3-Deoxy-1,2:5,6-di-*O*-isopropylidene-α-D-*ribo*-hexofuranose-3-spiro(3-oxocyclopentane) (23) and (3*S*)-3-deoxy-1,2:5,6di-*O*-isopropylidene-α-D-*ribo*-hexofuranose-3-spiro-(3-oxocyclopentane) (24)

To a solution of compound 21 (1.8 g, 6.1 mmol) in THF (10 mL) under N₂, was added BH₃·SMe₂.(0.6 mL, 6.7 mmol) at 0 °C. After 2 h, a saturated aq. solution of sodium acetate and H_2O_2 (30% solution, 0.8 mL, 7.3 mmol) were added at -15 °C. Solvent was removed and the residue extracted with EtOAc, washed with brine, dried (Na₂SO₄), and concentrated. The crude product was purified on silica gel using light petroleum-EtOAc (3 : 2) to give a residue (1.6 g, 5.1 mmol) which was added to a solution of (COCl)2 (1.0 mL, 10.2 mmol) and Me2SO (1.6 mL, 20.4 mmol) in CH₂Cl₂ (10 mL) under nitrogen at -78 °C. After 1 h at -78 °C, Et₃N (4.4 mL, 30.6 mmol) was added and allowed to attain rt. The reaction mixture was diluted with CH₂Cl₂, washed with water, brine, dried (Na₂SO₄) and concentrated. The crude product was purified on silica gel with light petroleum–EtOAc (5 : 1) to afford **23** (0.59 g), $[a]_{D}$ +89.11 (c 1.0 in CHCl₃); δ_H (500 MHz; CDCl₃) 1.33 (s, 6 H), 1.42,1.55 (2 s, 6 H), 1.95 (d, 1 H, J 17.8 Hz), 2.17–2.32 (m, 2 H), 2.35–2.47 (m, 2 H), 2.50 (d, 1 H, J 17.8 Hz), 3.88 (dt, 1 H, J 8.9, 3.2 Hz), 3.95 (m, 2 H), 4.16 (m, 1 H), 4.24 (d, 1 H, J 3.7 Hz), 5.73 (d, 1 H, J 3.7 Hz); δ_C (50 MHz; CDCl₃) 25.1, 26.4, 26.7, 26.9, 36.4, 43.0, 53.1, 68.8, 74.2, 82.2, 86.1, 104.1, 109.7, 112.2, 216.2; MS (EI) m/z 297 (M⁺ – CH₃) (Found: C, 61.65; H, 7.46. C₁₆H₂₄O₆ requires C, 61.52; H, 7.74%). Further elution afforded compound 24 (0.7 g), $[a]_{\rm D}$ + 32.3 (c 1.0 in CHCl₃); $\delta_{\rm H}$ (500 MHz; CDCl₃) 1.31 (s, 6 H), 1.38 (s, 3 H), 1.52 (s, 3 H), 1.65 (m, 1 H), 2.17-2.32 (m, 2 H), 2.46 (m, 1 H), 2.54 (ABq, 2 H, J 17.5 Hz), 3.87 (d, 1 H, J 9.4 Hz), 3.95 (dd, 1 H, J 5.2, 8.6 Hz), 4.07 (ddd, 1 H, J 9.4, 5.2, 6.2 Hz), 4.18 (dd, 1 H, J 6.2, 8.6 Hz), 4.30 (d, 1 H, J 3.2 Hz), 5.79 (d, 1 H, J 3.2 Hz); δ_C (50 MHz; CDCl₃) 24.9, 25.5, 26.1, 26.4, 26.6, 36.7, 41.8, 52.6, 68.6, 73.8, 81.8, 86.6, 103.9, 109.6, 111.9, 215.8; MS (EI) m/z 297 (M⁺ - CH₃) (Found: C, 61.38; H, 7.54. C₁₆H₂₄O₆ requires C, 61.52; H, 7.74%).

(3*R*)-3-Deoxy-1,2:5,6-di-*O*-isopropylidene-*a*-D-*ribo*-hexofuranose-3-spiro[3-(hydroxyethylidene)cyclopentane] (25)

Compound 23 (0.31 g, 1.0 mmol) in THF (4 mL) was added to a previously stirred solution of triethyl phosphonoacetate (0.25 mL, 1.3 mmol) and NaH (0.048 g, 1.2 mmol) in THF (5 mL) at 0 °C under N₂. After 0.5 h at rt, saturated aq. NH₄Cl was added and the solvent removed. The residue was extracted with EtOAc, washed with water, brine, dried and concentrated. The crude product was purified on silica gel by using light petroleum–EtOAc (3 : 2). The resulting product (0.32 g) was added to DIBAL-H (2 M solution in toluene, 1.0 mL, 2 mmol) in CH₂Cl₂ (8 mL) at -78 °C. After 0.5 h, saturated aq. NH₄Cl was added at -78 °C and the product diluted with CH₂Cl₂, washed with brine, dried and evaporated. The residue was passed through a short bed of silica gel eluting with EtOAc-light petroleum (1 : 1) to give **25** (0.26 g, overall yield for two steps 77%); $\delta_{\rm H}$ (200 MHz; CDCl₃) 1.30, 1.32, 1.40, 1.52 (4 s, 12 H), 1.88–2.07 (m, 3 H), 2.29–2.60 (m, 3 H), 3.85–4.17 (m, 7 H), 5.58 (m, 1 H), 5.70 (m, 1 H); $\delta_{\rm C}$ (50 MHz; CDCl₃) 25.2, 25.9, 26.3, 26.6, 26.8, 27.2, 27.5, 30.2, 32.6, 37.4, 55.0, 55.8, 59.9, 60.1, 68.4, 74.2, 81.1, 85.2, 85.4, 103.9, 109.2, 111.5, 121.5, 143.6; MS (EI) *m/z* 340 (M⁺) (Found: C, 63.59; H, 8.13. C₁₈H₂₈O₆ requires C, 63.51; H, 8.29%).

(3*R*)-3-Deoxy-1,2;5,6-di-*O*-isopropylidene-*a*-D-*ribo*-hexofuranose-3-spiro(3,3-diallylcyclopentane) (26)

Following the general procedure for cyclopropanation, 25 (0.13 g, 0.38 mmol), a 1 M solution of Et₂Zn (1.1 mL, 1.14 mmol) and CH₂I₂ (0.18 mL, 2.28 mmol) in dry CH₂Cl₂ (5 mL) gave the cyclopropylmethanol derivative (85 mg) which was converted into the xanthate derivative with NaH (19 mg, 0.48 mmol), CS₂ (0.06 mL, 0.96 mmol) and MeI (0.08 mL, 1.2 mmol). By following the general procedure for diallylation, the xanthate derivate (90 mg, 0.3 mmol), allyltri-n-butyltin (0.2 mL, 0.6 mmol) and AIBN (5 mg) gave 26 (26 mg, overall yield 19%), $[a]_{\rm D}$ +22.8 (c 1.1 in CHCl₃); $\delta_{\rm H}$ (200 MHz; CDCl₃) 0.97 (d, 1 H, J 14.4 Hz), 1.32, 1.34, 1.40, 1.50 (4 s, 12 H), 1.55-1.67 (m, 2 H), 1.75 (d, 1 H, J 14.4 Hz), 1.83-2.03 (m, 2 H), 2.15 (d, 4 H, J 6.4 Hz), 3.80–3.93 (m, 2 H), 4.01–4.20 (m, 2 H), 4.26 (d, 1 H, J 3.4 Hz), 4.94–5.10 (m, 4 H), 5.62 (d, 1 H, J 3.4 Hz), 5.66–5.92 (m, 2 H); δ_C (50 MHz; CDCl₃) 25.5, 26.5, 26.8, 27.1, 27.9, 35.5, 39.2, 43.3, 43.9, 45.7, 56.2, 69.1, 74.0, 82.8, 87.8, 104.1, 109.4, 111.9, 117.4, 135.4 (Found: C, 70.03; H, 9.13. C₂₂H₃₄O₅ requires C, 69.81; H, 9.05%).

(3*R*)-3-Deoxy-1,2;5,6-di-*O*-isopropylidene-α-D-*ribo*-hexofuranose-3-spirocyclopentane-3-spiro(3-cyclopentene) (27)

Following the general procedure for RCM, compound **26** (22 mg, 0.06 mmol), and Grubbs' catalyst (3 mg) in CH₂Cl₂ (5 mL) gave **27** (18 mg, 88%), $[a]_D$ +22.7 (*c* 0.5 in CHCl₃); δ_H (200 MHz; CDCl₃) 1.22 (d, 1 H, *J* 15.1 Hz), 1.32, 1.35, 1.41, 1.51 (4 s, 12 H), 1.55–1.74 (m, 2 H), 1.82–2.13 (m, 3 H), 2.34 (m, 4 H), 3.88 (m, 2 H), 4.11 (m, 2 H), 4.29 (d, 1 H, *J* 3.5 Hz), 5.62 (d, 1 H, *J* 3.5 Hz), 5.65 (s, 2H); δ_C (50 MHz; CDCl₃) 25.6, 26.6, 26.8, 27.2, 28.8, 39.5, 43.7, 47.0, 47.3, 50.3, 55.9, 69.1, 74.2, 83.1, 88.4, 104.3, 109.4, 111.8, 129.5, 130.0 (Found: C, 68.30; H, 8.69. C₂₀H₃₀O₅ requires C, 68.55; H, 8.63%).

(3S)-3-Deoxy-1,2;5,6-di-O-isopropylidene-α-D-*ribo*-hexofuranose-3-spiro-(3,3-diallylcyclopentane) (29)

Compound **29** was prepared from (**24**) (overall yield 8%) by following the same procedure described for **23**, $[a]_{\rm D}$ + 47.5 (*c* 1.0 in CHCl₃); $\delta_{\rm H}$ (200 MHz; CDCl₃) 1.31, 1.33, 1.39, 1.49 (4 s, 12 H), 1.57 (m, 3 H), 1.76–1.92 (m, 3 H), 2.11 (d, 4 H, *J* 7.3 Hz), 3.75–3.93 (m, 2 H), 3.98– 4.17 (m, 3 H), 4.98–5.08 (m, 4 H), 5.63 (d, 1 H, *J* 3.4 Hz), 5.72–5.93 (m, 2 H); $\delta_{\rm C}$ (50 MHz; CDCl₃) 25.7, 26.5, 26.8, 27.2, 29.0, 35.9, 38.0, 43.9, 44.1, 44.3, 55.9, 69.1, 74.2, 82.6, 87.7, 104.4, 109.4, 111.6, 117.0, 117.3, 135.7, 135.9 (Found: C, 69.82; H, 9.15. C₂₂H₃₄O₅ requires C, 69.81; H, 9.05%).

(3S)-3-Deoxy-1,2;5,6-di-O-isopropylidene-α-D-*ribo*-hexofuranose-3-spirocyclopentane-3-spiro(3-cyclopentene) (30)

Following the general procedure for RCM, compound **29** (30 mg, 0.08 mmol) and Grubbs' catalyst (4 mg) in CH₂Cl₂ (5 mL) gave **30** (24 mg, 87%), $[a]_{D}$ + 38.9 (*c* 0.85 in CHCl₃); δ_{H} (200 MHz; CDCl₃) 1.32, 1.34, 1.40, 1.49 (4 s, 12 H), 1.55–

1.87 (m, 4 H), 1.93 (d, 1 H, J 14.2 Hz), 2.11 (d, 1 H, J 14.2 Hz), 2.20–2.41 (m, 4 H), 3.79–3.94 (m, 2 H), 4.04–4.20 (m, 3 H), 5.63 (m, 3 H); $\delta_{\rm C}$ (50 MHz; CDCl₃) 25.6, 26.5, 26.8, 27.1, 30.0, 39.9, 42.2, 46.6, 47.3, 49.0, 55.5, 69.0, 74.1, 82.9, 88.8, 104.3, 109.4, 111.6, 129.4, 130.0 (Found: C, 68.80; H, 8.78. C₂₀H₃₀O₅ requires C, 68.55; H, 8.63%).

(5*S*)-(5-*tert*-Butyldiphenylsilyloxymethyl)-1-(toluene-4-sulfonyl)pyrrolidin-3-one (32)

A mixture of compound 31 (2.3 g, 8.5 mmol), TBDPSCl (2.4 mL, 9.35 mmol) and imidazole (0.64 g, 9.35 mmol) in DMF (15 mL) was stirred overnight. The reaction mixture was diluted with water, extracted with EtOEt, dried (Na₂SO₄) and concentrated. The residue was passed through a short column of silica gel with light petroleum-ethyl acetate (4 : 1). The product (3.0 g, 5.9 mmol) was treated with PDC (3.0 g, 8.0 mmol) and powdered molecular sieves 4 Å (3.0 g) in CH₂Cl₂ (100 mL). After stirring at rt for 4 h, the mixture was filtered through a bed of silica gel with EtOEt as eluent. The filtrate was concentrated and crystallized from CHCl₃ to give 32 (2.6 g, 60%); mp 144 °C; [a]_D + 34 (c 1.0 in CHCl₃); IR (CHCl₃) 1764 cm⁻¹ (C=O); δ_H (200 MHz; CDCl₃) 1.00 (s, 9 H), 2.3 (m, 2 H), 2.42 (s, 3 H), 3.58 (dd, 1 H, J 2.3, 10.3 Hz), 3.82 (ABq, 2 H, J 18.7 Hz), 4.00 (dd, 1 H, J 3.3, 10.3 Hz), 4.32 (m, 1 H), 7.55 (m, 14 H); δ_c (50 MHz; CDCl₃) 19.0, 21.5, 26.6, 40.0, 54.0, 58.0, 67.9, 127.0–143.8, 208.6; MS (EI) *m*/*z* 450 (M⁺ - ^tBu) (Found: C, 66.03; H, 6.68; N, 2.66; S, 6.46. C₂₈H₃₃NO₄SSi requires C, 66.24; H, 6.55; N, 2.76; S, 6.32%).

(5*S*,2*E*,*Z*)[(5-*tert*-Butyldiphenylsilyloxymethyl)-1-(toluene-4-sulfonyl)pyrrolidin-3-ylidene]ethanol (33)

A solution of compound 32 (4.0 g, 7.9 mmol), Ph₃P=CHCO₂Et (5.48 g, 15.8 mmol) in benzene (25 mL) was heated under reflux for 24 h. Solvent was removed and the residue passed through a short column of silica gel with light petroleum-ethyl acetate (19:1) to give the α , β -unsaturated ester (4.18 g) which was taken in CH₂Cl₂ (50 mL) and cooled to -78 °C. DIBAL-H (2 M solution in toluene, 8.3 mL, 16.6 mmol) was introduced. After stirring at -78 °C for 45 min., excess DIBAL was quenched by addition of saturated solution of sodium potassium tartrate. The mixture was stirred at rt for 3 h, filtered, and concentrated. The product was purified on silica gel by using light petroleum-ethyl acetate (4 : 1) to give 33 (3.6 g, 85%); δ_H (200 MHz; CDCl₃) 1.08 (s, 9 H), 2.14–2.69 (m, 2 H), 2.43 (s, 3 H), 3.48-4.0 (m, 7 H), 5.43 (m, 1 H), 7.20-7.74 (m, 14 H); $\delta_{\rm C}$ (50 MHz; CDCl₃) 19.0, 21.2, 26.6, 30.2, 34.6. 49.1, 52.7, 59.6, 60.6, 65.7, 66.1, 121.5-137.4, 143.1; MS (EI) m/z 478 (M⁺ - ^tBu) (Found: C, 67.59; H, 7.12; N, 2.44; S, 5.78. C₃₀H₃₇NO₄SSi requires C, 67.25; H, 6.96; N, 2.61; S, 5.98%).

(2*S*)-(2-*tert*-Butyldiphenylsilyloxymethyl)-4,4'-diallyl-1-(toluene-4-sulfonyl)pyrrolidine (35)

Cyclopropanation of 33 was done as described earlier using $Et_2Zn-CH_2I_2$ to give 34 (0.8 g, 78%); δ_H (200 MHz; CDCl₃) 0.10 (m, 1 H), 0.45 (m, 1 H), 0.75-2.0 (m, 3 H), 1.11 (s, 9 H), 2.44 (s, 3 H), 3.0–4.25 (m, 7 H), 7.30 (m, 14 H); $\delta_{\rm C}$ (50 MHz; CDCl₃) 19.0, 21.2, 24.1, 24.6, 26.8, 30.6, 37.0, 51.0, 56.6, 60.5, 60.7, 62.5, 63.1, 65.5, 127.5-135.4, 143.0; MS (EI) m/z: 548 $(M^+ - 1)$. Subsequent bromination and allylation reactions as per general procedure, afforded 35 (0.55 g, 66%) (contaminated with trace amount of tin reagent and used as such for the next reaction); $\delta_{\rm H}$ (200 MHz; CDCl₃) 1.05 (s, 9 H), 1.59 (m, 3 H), 1.81 (dd, 1 H, J 3.1, 6.3 Hz), 2.06 (d, 2 H, J 6.3 Hz), 2.38 (s, 3 H), 3.16 (ABq, 2 H, J 10.9 Hz), 3.66 (m, 1 H), 3.79 (dd, 1 H, J 6.7, 10.1 Hz), 4.01 (dd, 1 H, J 3.3, 10.1 Hz), 4.8 (m, 4 H), 5.7 (m, 2 H), 7.1–7.6 (m, 14 H); $\delta_{\rm C}$ (75 MHz; CDCl₃) 19.25, 21.4, 26.9, 38.85, 39.4, 40.7, 43.7, 58.2, 60.0, 66.3, 118.2, 127.3-136.0, 142.9; MS (EI) m/z 516 (M⁺ - ^tBu).

(3S)-[2-(Toluene-4-sulfonly)-2-azaspiro[4.4]non-7-en-3-yl]methanol (37)

Compound 35 was subjected to RCM reaction to afford 36 (0.31 g, 96%); { $\delta_{\rm H}$ (200 MHz; CDCl₃) 1.06 (s, 9 H), 1.7–2.3 (m, 6 H), 2.43 (s, 3 H), 3.19 (ABq, 2 H, J 9.5 Hz), 3.60 (m, 1 H), 3.69 (t, 1 H, J 9.5 Hz), 4.11 (dd, 1 H, J 3.2, 9.5 Hz), 5.50 (m, 2 H), 7.2–7.7 (m, 14 H); δ_c (50 MHz; CDCl₃) 19.8, 22.1, 27.5, 42.6, 43.8, 44.8, 48.0, 61.2, 61.7, 67.0, 128.1-136.1, 141.7} and then treated with n-Bu₄NF (1 M solution in THF, 1.5 mL, 1.5 mmol) in THF (5 mL) at rt for 1 h. Solvent was removed and the residue purified on a short silica gel column using light petroleum–ethyl acetate (4 : 1) to give **37** (0.16 g, 93%), $[a]_{\rm D}$ – 38 (c 0.7 in CHCl₃); δ_H (200 MHz; CDCl₃) 1.5–2.0 (m, 4 H), 2.32 (m, 2 H), 2.48 (s, 3 H), 3.32 (ABq, 2 H, J 9.7 Hz), 2.64 (m, 1 H), 2.76 (br d, 2 H), 5.42 (m, 1 H), 5.58 (m, 1 H), 7.35 (d, 2 H, J7.7 Hz), 7.74 (d, 2 H, J 7.7 Hz); δ_c (50 MHz; CDCl₃) 21.3, 42.1, 42.5, 43.4, 46.8, 61.4, 62.1, 65.5, 127.4-129.4, 143.4; MS (EI) m/z 292 (M⁺ - 1) (Found: C, 62.70; H, 7.02; N, 4.19; S, 10.26. C₁₆H₂₁NO₃S requires C, 62.51; H, 6.89; N, 4.56; S, 10.43%).

(3*S*)-[2-(Toluene-4-sulfonyl)-2-azaspiro[4.4]nonan-3-yl]methanol (38)

Compound **37** (0.155 g, 0.5 mmol) and 10% Pd/C (0.02 g) in methanol (5 mL) were stirred under hydrogen atmosphere at normal temperature and pressure (ntp) for 3 h. The catalyst was filtered and the filtrate concentrated to give **38** (0.15 g, 96%); $[a]_{\rm D}-15$ (*c* 0.7 in CHCl₃); $\delta_{\rm H}$ (200 MHz; CDCl₃) 0.86 (m, 2 H), 1.52 (m, 6 H), 1.75 (m, 2 H), 2.46 (s, 3 H), 3.23 (ABq, 2 H, *J* 9.5 Hz), 3.58 (m, 1 H), 3.78 (br s, 2 H), 7.35 (d, 2 H, *J* 7.6 Hz), 7.73 (d, 2 H, *J* 7.6 Hz); $\delta_{\rm C}$ (50 MHz; CDCl₃) 21.3, 24.1, 35.9, 36.4, 41.2, 48.0, 60.5, 62.2, 65.7, 127.3, 129.4, 133.9, 143.5 (Found: C, 61.93; H, 7.76; N, 4.39; S, 10.39. C₁₆H₂₃NO₃S requires C, 62.11; H, 7.49; N, 4.53; S, 10.36%).

(3*S*)-2-(Toluene-4-sulfonyl)-2-azaspiro[4.4]nonane-3-carboxylic acid (39)

A mixture of **38** (0.13 g, 0.42 mmol), CH₃CN (2 mL), CCl₄ (2 mL), H₂O (2 mL), NaIO₄ (0.1g, 1.32 mmol) and RuCl₃(H₂O)_n (0.02 g) was vigorously stirred at rt for 2 h. The reaction mixture was filtered through a pad of celite, the filtrate concentrated and the residue purified on silica gel by using ethyl acetate afforded **39** (0.1 g, 77%); $[a]_D - 67 (c \ 0.7 \text{ in CHCl}_3)$; IR (CHCl₃) 1726 (C=O), 3012 cm⁻¹ (OH); δ_H (200 MHz; CDCl₃) 1.18 (m, 2 H), 1.52 (m, 6 H), 2.05 (m, 2 H), 2.41 (s, 3 H), 3.18 (ABq, 2 H. J 9.1 Hz), 4.20 (t, 1 H, J 8.2 Hz), 7.29 (d, 2 H, J 9.1 Hz), 7.73 (d, 2 H, J 9.1 Hz), 10.7 (br. s, 1 H); δ_C (50 MHz; CDCl₃) 21.4, 24.3, 24.5, 35.8, 36.3, 42.5, 49.7, 59.1, 60.4, 127.6, 129.6, 134.7, 143.6, 177.0; MS (EI) *m*/*z* 278 (M⁺ - CO₂) (Found: C, 59.06; H, 6.80; N, 4.15; S, 9.63. C₁₆H₂₁NO₄S requires C, 59.42; H, 6.54; N, 4.33; S, 9.91%).

Acknowledgements

SVR, KS, JC and SK are grateful to CSIR, New Delhi for the award of research fellowships.

References

- M. Sannigrahi, *Tetrahedron*, 1999, **55**, 9007; A. P. Krapcho, *Synthesis*, 1974, 363; E. J. Corey and A. Gizman-Perez, *Angew. Chem. Int. Ed. Engl.*, 1998, **37**, 389.
- 2 G. Firour, G. Cahiez and J. F. Normant, *Synthesis*, 1984, 37; L. Manzoni, M. Colombo, E. May and C. Scolastico, *Tetrahedron*, 2001, 57, 249.
- 3 L. A. Paquette, R. T. Bibart, C. K. Seekamp and A. L. Kahane, *Org. Lett.*, 2001, **3**, 4039; L. A. Paquette, D. R. Owen, R. T. Bibart and C. K. Seekamp, *Org. Lett.*, 2001, **3**, 4043.
- 4 K. K.-I. Tadano, S. Kanazawa, H. Yamada and S. Ogawa, Carbohydr. Res., 1988, 184, 271; G. Chen, Z. B. Fei, X. Huang,

Y. Xie, J. Xu, J. Gola, M. Steng and J. Praly, Eur. J. Org. Chem., 2001, 2939.

- 5 R. R. Schrock, J. S. Murdzek, G. C. Mazan, J. Robbins, M. DiMare
- and M. O'Regan, J. Am. Chem. Soc., 1990, 112, 3875.
 S. T. Nguyen, L. K. Johnson, R. H. Grubbs and J. W. Ziller, J. Am. Chem. Soc., 1992, 114, 3974; S. T. Nguyen, R. H. Grubbs and J. W. Ziller, J. Am. Chem. Soc., 1993, 115, 9858.
- 7 For recent reviews, see R. H. Grubbs and S. Chang, Tetrahedron, 1998, 54, 4413; A. Furstner, Angew. Chem. Int. Ed., 2000, 39, 3012.
- 8 S. Kurosawa, M. Bando and K. Mori, Eur. J. Org. Chem., 2001, 4395; P. S. Aburel, C. Romming, K. Ma and K. Undheim, J. Chem. Soc. Perkin Trans. 1, 2001, 1458; K. Undheim and J. Efsking, Tetrahedron, 2000, 56, 4847; M. J. Bassindale, P. Hamely, A. leitner and J. P. A. Harrity, Tetrahedron Lett., 1999, 40, 3247; S. Suga, M. Watanabe and J. Yoshida, J. Am. Chem. Soc., 2002, 124, 14824.
- 9 M. Bassindale, A. Edwards, P. Hamley, H. Adams and J. P. Harrity, Chem. Commun., 2000, 1035.
- 10 R. K. Singh, Synthesis, 1985, 54; S. Kotha and N. Sreenivaschary, *Bioorg. Med. Chem. Lett.*, 1988, **8**, 257; S. Kotha and E. Brahmachary, *Tetrahedron Lett.*, 1997, **3**, 3561.
- 11 M. K. Gurjar, B. V. N. B. S. Sarma and B. V. Rao, J. Carbohydr. Chem., 1998, 17, 1107.

- 12 G. E. Keck, E. J. Enholm, J. B. Yates and M. R. Wiley, Tetrahedron, 1984, 41, 4079; S. Hanessian and M. Alpegiani, Tetrahedron, 1989, 45, 941; Y. Yamamoto and N. Asao, Chem. Rev., 1993, 93, 2207.
- 13 M. K. Gurjar, S. V. Ravindranadh and S. Karmakar, Chem. Commun., 2001, 241.
- 14 E. J. Corey and M. Chaykovsky, J. Am. Chem. Soc., 1965, 87, 1353.
- 15 J. Furukawa, N. Kawabata and J. Nishimura, Tetrahedron, 1968, 24, 53.
- 16 J. M. Tronchet and B. Gentile, Carbohydr. Res., 1975, 44, 23.
- 17 M. Kawana and S. Emoto, Tetrahedron Lett., 1975, 39, 3395. 18 L. Strekowski, M. Visnick and M. A. Battiste, Tetrahedron Lett.,
- 1984. 25. 5603.
- 19 A. Arai and I. Ichikizaki, Bull. Chem. Soc. Jpn., 1961, 34, 1571.
- 20 V. Teetz and H. Gaul, Tetrahedron Lett., 1984, 25, 4483; V. Teetz, H. K. Urbach and R. Becker, U. S. Patent 4,558,064, 1985; Schering Corporation, EPA 50800(1982) Hoechst Aktiengesellschaft, DOS 3211397(1983) For a review on proline derivatives, see A. B. Mauger and B. Witkop, *Chem. Rev.*, 1966, **66**, 47; L. Manzoni, M. Colombo, E. May and C. Scolastico, *Tetrahedron*, 2001, **57**, 249.
- 21 K. Achiwa, U. S. Patent 4,879,389, 1989; J. M. Manning and A. Meister, Biochem., 1966, 5, 1154.